Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

05 Mar 2017 - 09 Mar 2017
20 Mar 2017 - 23 Mar 2017
12 Apr 2017 - 14 Apr 2017

Fine-Tuning Liver Glucose Metabolism

By Biotechdaily staff writers
Posted on 30 Jun 2006
ADVERTISEMENT
SARTORIUS AG
Researchers have traced the biochemical mechanism responsible for modulating the uptake, release, and synthesis of glucose by the liver.

Previous findings had shown that hormonal and nutrient regulation of glucose synthesis in the liver was controlled by modulation of the transcriptional coactivator protein PGC-1-alpha. In the current study, investigators at Johns Hopkins University (Baltimore, MD, USA) learned that PGC-1-alpha resides in a multi-protein complex containing the acetyltransferase GCN5. Fine-tuning of glucose metabolism depends on inactivation of PGC-1-alpha by this enzyme and its subsequent sequestering away from the genes it was normally meant to activate.

This mechanism was demonstrated experimentally by using an adenovirus vector to implant the gene for GCN5 into the livers of a group of starved mice. Normally such animals are actively releasing glucose into the blood, but results published in the June 2006 issue of Cell Metabolism showed that glucose release in these genetically engineered animals was significantly reduced.

"These results show that changing GCN5 is sufficient to control the sugar balance in mice,” explained senior author Dr. Pere Puigserver, assistant professor of cell biology at Johns Hopkins University. "Therefore, GCN5 has the potential to be a target for therapeutic drug design in the future. Understanding the ways that energy production and use are controlled is crucial to developing new drugs and therapies.”



Related Links:
Johns Hopkins University

Channels

Business

view channel

Collaborative Agreement to Aid in Setting Guidelines for Evaluating Potential Ebola Therapy

Cooperation between an Israeli biopharmaceutical company and medical branches of the US government is designed to set ground rules for continued evaluation of an experimental therapy for Ebola virus disease. RedHill Biopharma Ltd. (Tel Aviv, Israel), a biopharmaceutical company primarily focused on development and c... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.